C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 401/14 (2006.01) A61K 31/4709 (2006.01) A61K 31/496 (2006.01) A61P 3/10 (2006.01) A61P 9/10 (2006.01) C07D 217/24 (2006.01) C07D 401/10 (2006.01) C07D 401/12 (2006.01) C07D 405/14 (2006.01)
Patent
CA 2644929
This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.
L'invention concerne des composés qui sont des agonistes de somatostatine et des récepteurs de somatostatine sélectifs de sous-type SSTR2. Les composés selon l'invention sont utiles dans le traitement et la prévention du diabète et des pathologies liées au diabète, notamment la rétinopathie, la neuropathie et la néphropathie. Bon nombre de ces composés sont oralement actifs. L'invention concerne également les stéréoisomères spécifiques préférés des ces agonistes de somatostatine. L'invention concerne encore des procédés de préparation de ces composés, ainsi que des méthodes et des compositions utilisant ces composés comme principe actif.
Eastman Brian
Lindsley Craig W.
Wolkenberg Scott E.
Zhao Zhijian
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Somatostatin agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Somatostatin agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatostatin agonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1478351